Calendar

2016 Scrip Awards

Quintiles’ Clinical Advance of the Year Award

Summit Therapeutics’ Phase 2 CoDIFy study of ridinilazole in Clostridium difficile infection

Stocks

Share Price

LSE: SUMM
199.05p -0.95
at 02:08pm GMT 23 Mar 2017

NASDAQ: SMMT
$12.54 -0.41
at 11:36am ET 23 Mar 2017

Current Programmes

  • C. Difficile Infections banner image

    C. difficile Infection

    Clostridium difficile infection (‘CDI’) is a major healthcare issue in hospitals, long-term care homes, and increasingly in the wider community. It is a serious illness caused by infection of the colon by the bacteria, C. difficile, which produces toxins that cause inflammation, severe diarrhoea and can in the most serious of cases be fatal.

    Read More
  • Duchenne Muscular Dystrophy image boy

    Duchenne Muscular Dystrophy

    Duchenne Muscular Dystrophy (‘DMD’) is a fatal, genetic disease that predominantly affects boys. It has a population of around 50,000 in the developed world and is classified as a rare or orphan disease. DMD is caused by the absence of a protein called dystrophin which is essential in maintaining the healthy function of muscles in the body.

    Currently there is no disease modifying treatment for all patients with DMD.

    Read More